



- (51) **International Patent Classification:**
A61K 39/395 (2006.01) *C07K 16/16* (2006.01)
- (21) **International Application Number:**
PCT/EP2013/059696
- (22) **International Filing Date:**
10 May 2013 (10.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/645,855 11 May 2012 (11.05.2012) US
- (71) **Applicant** (*for all designated States except US*): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) **Inventors; and**
- (71) **Applicants** (*for US only*): **HEKMAT, Dariusch** [DE/DE]; c/o Institute of Biochemical Engineering, Technische Universität München, Boltzmannstrasse 15, 85748 Garching (DE). **HELK, Bernhard** [DE/CH]; c/o Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel (CH). **SCHULZ, Henk, Konrad** [DE/CH]; c/o Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel (CH). **SMEJKAL, Benjamin** [DE/DE]; c/o Institute of Biochemical Engineering, Technische Universität München, Boltzmannstrasse 15, 85748 Garching (DE).

- (74) **Agent:** **LEHMEIER, Thomas**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*

(54) **Title:** CRYSTALLIZATION METHODS FOR PURIFICATION OF MONOCLONAL ANTIBODIES

(57) **Abstract:** This disclosure relates to methods for crystallization of antibodies from cell-free culture supernatant.

